Spectrum Pharmaceuticals and Allos Therapeutics Announce Additional Extension of Tender Offer Period for Shares of Allos Therapeutics HENDERSON, Nev. & WESTMINSTER, Colo.–(BUSINESS WIRE)–Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (Spectrum) and Allos Therapeutics, Inc. (NasdaqGS: ALTH) (Allos) today announced that Spectrum has provided an additional extension of the offer period in connection with its tender offer to [...]

Don’t Let the Bedbugs Bite, or No One Sleeps Tight LANGHORNE, Pa.–(BUSINESS WIRE)–Don’t let the bedbugs bite, or no one sleeps tight; Pronto Plus® and Michael Colongione release 5 tips for staying bedbug-free while traveling this summer. Teva to Host Conference Call and Webcast on May 24, 2012 JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) [...]

L’Oreal Active Cosmetics Division Deploys Cegedim Relationship Management’s Award Winning* Mobile Intelligence CRM in India PARIS–(BUSINESS WIRE)–L’Oreal Active Cosmetics Division Deploys Mobile Intelligence Cloud-Based CRM in India L’Oreal Active Cosmetics Division Deploys Cegedim Relationship Management’s Award Winning* Mobile Intelligence CRM in India PARIS–(BUSINESS WIRE)–Cegedim Relationship Management today announced that L’Oreal’s Active Cosmetics Division (ACD) has [...]

Sucampo Presents Detailed Results of Positive Phase 3 Trial of Lubiprostone in Opioid-Induced Bowel Dysfunction (OBD) BETHESDA, Md.–(BUSINESS WIRE)–Sucampo reported details from a phase 3 trial of AMITIZA for OBD in patients with chronic non-cancer pain, excluding those taking methadone, at DDW 2012. Early and Late Stage Innovators and Investors Meet at C21 BioVentures in [...]

Sucampo Presents Data for AMITIZA® in the Treatment of Moderate to Very Severe Irritable Bowel Syndrome with Constipation (IBS-C) BETHESDA, Md.–(BUSINESS WIRE)–Sucampo reported post-hoc analysis results from AMITIZA in IBS-C phase 3 trials showing a significantly higher proportion of treated patients vs. placebo received consistent relief of symptoms at DDW Cobiprostone Preclinical Data from NSAID-Induced [...]

Taro to Announce Financial Results for the Quarter Ended March 31, 2012 HAWTHORNE, N.Y.–(BUSINESS WIRE)–Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”), announced today that it will release its financial results for the quarter ended March 31, 2012 after market close on Thursday, May 24, 2012. Additionally, the release will be accessible on Taro’s website at [...]

Emergent BioSolutions Receives FDA Approval for BioThrax Administered Intramuscularly in a Three-Dose Primary Series Followed by Booster Doses ROCKVILLE, Md.–(BUSINESS WIRE)–Emergent BioSolutions Inc. (NYSE: EBS) announced today that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) to change the administration schedule of BioThrax® (Anthrax Vaccine Adsorbed) to a [...]

Partnering Bootcamp Kicks Off ChinaBio® Partnering Forum 2012 in Suzhou CARLSBAD, Calif. & SUZHOU, China–(BUSINESS WIRE)–ChinaBio® Partnering Forum 2012 will be held at the Kempinski Hotel Suzhou May 23–24 in Suzhou, China with a special Partnering Bootcamp – a half-day pre-conference program – held May 22. Array BioPharma and Genentech’s Strategic Alliance Voted Breakthrough Alliance [...]

Vascular Expert Supports FDA Warning about Experimental Therapy for MS Patients MIAMI–(BUSINESS WIRE)–Vascular expert Barry Katzen, M.D., pushes for new clinical trials to confirm experimental hi-risk therapy benefits multiple sclerosis patients. Galectin Therapeutics Reports First Quarter 2012 Financial Results NEWTON, Mass.–(BUSINESS WIRE)–Galectin Therapeutics announces first quarter 2011 results. FDA Advisory Committee Supports Approval of Gilead’s [...]

FDA Advisory Committee Supports Approval of Gilead’s Truvada® for Reducing the Risk of Acquiring HIV FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted to support approval of once-daily oral Truvada® (emtricitabine and tenofovir disoproxil fumarate) to reduce the [...]